Discounts may vary, but members can save an average of 24% off some prescription drugs not covered by our pharmacy benefits
One of the most common questions we hear from patients is: How long do I have to stay on this medication? Its a fair question, especially when it comes to something as personal (and sometimes expensive) as a GLP-1 prescription
Abbreviations ACEis: Angiotensin-converting enzyme inhibitors ARBs: Angiotensin receptor blockers CV: Cardiovascular CKD: Chronic kidney disease CREDENCE trial: Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial ESKD: End-stage kidney disease eGFR: Estimated glomerular filtration rate FIDELIO-DKD trial: Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial FIGARO-DKD trial: Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial GLP-1 RAs: Glucagon-like peptide-1 receptor agonists MOA: Mechanisms of action MR: Mineralocorticoid receptor MRA: Mineralocorticoid receptor antagonist RAAS inhibitors: Renin angiotensin-aldosterone system inhibitors SGLT2is: Sodium-glucose cotransporter-2 inhibitors T2D: Type 2 diabetes References Kovesdy CP
This article examines the mechanisms, potential risks, current evidence, and UK regulatory context to help you make an informed decision
Protocol 4: the medication transition plan Goal: Switch between GLP-1 medications without losing coverage or creating dangerous overlap Schedule (example: tirzepatide to semaglutide): Take last tirzepatide dose on day 0 Begin semaglutide at starting dose (0.25 mg) on day 7 Follow standard semaglutide escalation from there Why the plotter supports this: The plotter shows that seven days after your last tirzepatide dose, approximately 38% remains in your system
They found that 21 of 33 tumor types have Nrf2 mutations (Mitsuishi et al., 2012)
